STAT Plus: Bristol scrambles to push Celgene deal, but are the odds as high as some think?
MEL EVANS/AP
Bristol-Myers Squibb called a meeting with analysts in a “semi-urgent fashion” in hopes of convincing investors its bid for Celgene is a good deal.
No hay comentarios:
Publicar un comentario